Royalty Report: Drugs, Pain, Delivery – Collection: 319516

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Pain
  • Delivery
  • Pharmaceuticals
  • Medical
  • Biotechnology
  • Wound Care
  • Therapeutic
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 319516

License Grant
Licensee entered into an exclusive global license and sub-license from the Israel Licensor for the rights to discover, make, sell, market, and otherwise commercialize Licensed Compound or any pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a Licensed Compound (Licensed Product).
License Property
Licensed Compound means bupivacaine liposome, in injectable gel or suspension.

Licensed Product means any pharmaceutical composition or preparation (in any and all dosage forms) in final form such as LBL100 or ProbudurTM.

LBL100 or ProbudurTM means Long-acting Bupivacaine Liposomal-gel 3.0% which is a drug product candidate based on a unique liposomal delivery system utilizing large multi-vesicular vesicles (“LMVVs”) encapsulating a high dose of the local anesthetic bupivacaine. These drug-loaded liposomes are composed of lecithin and cholesterol which are generally recognized as safe (“GRAS”) by the FDA. These LMVVs are embedded in hydrogel beads to form a Lipogel. The system delivers a local anesthetic/analgesic medicine from the Lipogel. This this product candidate could potentially eliminate the need for opioids for post-operative pain relief.

Probudur is the product candidate covered by US Patent No. 9,713,591. The patent contains composition claims to pharmaceutical compositions having an external storage solution containing an active pharmaceutical ingredient and particles of liposomes embedded in a polymeric matrix contained within the storage solution.

9,713,591 – Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same

Licensor develops a number of highly-potent therapeutics utilizing proprietary liposome-based nano-drugs with novel drug-loading-capabilities and drug-release mechanisms. Licensors proprietary platform implements a highly-efficient innovative approach which allows for the remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site.

Field of Use
The field of use is for the treatment of pain control to be used for general surgeons, anesthesiologists, and orthopedic surgeons. Probudur may provide pain control for up to 96 hours.

LBL100 (3% bupivacaine in Lipogel), is being developed as a long-acting local anesthetic for post-operative pain.

LBL100 is a drug product based on a type of liposomal delivery system with large multi-vesicular vesicles (LMVVs) encapsulating a very high dose of the local anesthetic bupivacaine in a unique way. These drug-loaded liposomes are composed of lecithin and cholesterol; both lipids are “GRAS” (Generally Recognized As Safe). These LMVVs are embedded in hydrogel beads to form a lipogel. The system delivers a local analgesic medicine from the Lipogel that is intended to provide improved onset, duration and peak performance properties. With early studies indicating it can provide pain control for up to 96 hours, the formulation has shown the potential to reduce reliance on opioid pain management to improve quality of care and hospital economics.

IPSCIO Record ID: 369241

License Grant
Licensor grants to the Licensee of Ireland
– the exclusive right and license to make, have made, use, offer for sale, sell and import the Product in the Territory, including the right to record sales for its own account;
– in each case, solely for use in the Field and Territory and in connection with Licensees development and Commercialization of the Product and to otherwise exercise Licensees rights and perform its obligations under this Agreement
Know-How;
— an exclusive license under the Product Patents Rights and Product
— an exclusive license under the SAIB Patent Rights;
— an exclusive license under the Re-appliable Patent Rights; and
— an exclusive sublicense under Licensors license to the Epicept Intellectual Property; and,
– an exclusive license and right of cross-reference to all Development Data Controlled by Licensor in existence as of the Effective Date solely to exercise its rights and licenses under this Agreement with respect to the Product.

Licensor grants an exclusive license to use the Licensor Trademark in the Territory solely in connection with the Commercialization of Product in the Territory.

License Property
Licensor is the owner of a proprietary product for pain treatment consisting of a bupivacaine transdermal patch as described below and certain patents and know-how relating thereto.

Product means the product under development by Licensor currently known as ELADURâ„¢.

Bupivacaine means 1-butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide, including any and all pharmaceutically acceptable salts, solvates, prodrugs, esters, free base forms, enantiomers (and racemic or other mixtures of said enantiomers) thereof.

Topical Bupivacaine Product means any formulation containing Bupivacaine, either alone or in combination with one or more other active ingredients. for use in the Field.

Licensor Trademark means the trademark rights to the mark ELADURâ„¢ and similar rights under the laws of any Governmental Entity, including all goodwill associated therewith, and all applications, registrations, extensions and renewals relating thereto.

Patents rights include Transdermal Delivery System, and, Methods for Transdermal Drug Administration.

Field of Use
ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

Bupivacaine is a prescription medication used as a local anesthetic (numbing medicine). Bupivacaine blocks the nerve impulses that send pain signals to your brain.  Bupivacaine injection is used to numb an area of your body during or after surgery or other procedures, childbirth, or dental work.

The Field means all pharmaceutical applications, including the treatment of pain, for human health.

IPSCIO Record ID: 26586

License Grant
Licensee shall have the exclusive right to Commercialize each of the Licensed Products in the Territory.  Saber Delivery System a patented and versatile depot injectable useful for protein and small molecule delivery that can be formulated for systemic or local administration.
License Property
The advantages of Saber may include reduced side effects, longer duration and smaller injection volume. Our first application is for controlled delivery of bupivacaine for post-operative pain relief (Saber-Bupivacaine), for which we own all worldwide rights. Saber-Bupivacaine is currently in Phase II clinical trials. We are developing Saber-Bupivacaine, a sustained-release formulation of bupivacaine, a local anesthetic, using our Saber delivery system for the treatment of post-surgical pain.

IPSCIO Record ID: 256269

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses under the Licensor Licensed Patents and Patents within the Licensor Improvements to make, have made, develop, use, sell, offer for sale, have sold, and import Licensed Products in and for the Field throughout the Territory.
License Property
Licensor has certain patent rights relating to methods and compositions for use in the topical treatment of back pain, muscle tensions and myo-fascial pain, where such methods and compositions feature a topical carrier system containing a local anesthetic agent and are intended for use on intact mammalian skin and/or outer synovial membranes, and certain additional patent rights relating to methods and compositions that include the use of certain intradermal pharmaceutical penetration enhancing excipients.

“Licensed Product” means a transdermal pharmaceutical patch product for sale only by prescription containing bupivacaine as the only active ingredient, indicated and approved by a Regulatory Authority for use in the Field, wherein such product and/or indication is covered by a Valid Claim of the EpiCept Licensed Patents or a Valid Claim of a Patent under the EpiCept Improvements.

Field of Use
The Field shall mean all pharmaceutical applications for the palliative, prophylactic and/or therapeutic treatment of Back Pain in humans.

IPSCIO Record ID: 356970

License Grant
For the Option Grant, Licensor of Canada grants the exclusive option. exercisable by Licensee during the Option Period, to obtain an exclusive license, with the right to sublicense through multiple tiers of sublicense, under the Licensors Technology and the Licensors Product Technology to make, have made, import, use, offer for sale, sell and have sold Licensed Products in the Field in the Territory.

Upon exercise of the option,  Licensor grants this exclusive license.

Licensee shall have the right to reference any Licensor DMFs applicable to the Licensed Product.

License Property
Patents relate to Cross-linked high amylase starch for use in controlled-release pharmaceutical formulations and processes for its manufacture, and, Misuse Preventative, Controlled Release Formulation.

Patents relate to the development of abuse deterrent formulation of hydrocodone for the treatment or relief of pain using Altus' Intellitabâ„¢ drug delivery platform.

Field of Use
Field shall mean the treatment or relief of pain, pain syndromes or pain associated with medical conditions or procedures in humans.

IPSCIO Record ID: 27640

License Grant
In this Agreement with Irish Licensor Subsidiary, the Licensee of Ireland is obligated to pay the Licensor a royalty on sales of XaraColl in the United States . Licensee also agreed to pay a royalty on sales of Cogenzia outside of the United States.
License Property
XaraColl® for the treatment of post-operative pain and Cogenzia® for the treatment of diabetic foot infections. These products combine proven therapeutics, including small molecules and biologics, with highly customized drug release profiles, localized drug delivery and superior handling properties.

XaraColl, is an implantable, bioresorbable collagen sponge designed to provide sustained post-operative pain relief, or analgesia, through controlled delivery of bupivacaine hydrochloride, or bupivacaine, at the surgical site. Bupivacaine is a local anesthetic drug.

Field of Use
The Licensee develops localized drug delivery technologies.

IPSCIO Record ID: 314332

License Grant
Licensor grants to the Licensee of Denmark and its Affiliates a worldwide, exclusive license, with the right to sublicense, to the Licensed Patents and Licensed Know-How, to research, develop, make, have made, use, import, export, sell, offer for sale, and otherwise transfer the Licensed Product in the Territory.

Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoam® delivery system in order to develop and commercialize  formulations of Liraglutide.

License Property
Licensor is a biopharmaceutical company specializing in the discovery, development and commercialization of DepoFoam® a proprietary injectable sustained-release delivery system (multivesicular liposomes).

Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.

Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.

Field of Use
DepoFoam is a drug delivery technology which consists of multi-vesicular liposome particles that contain internal chambers for encapsulated drugs. DepoFoam is capable of sustained release of a drug over a period of between one and 30 days. It works with narrow gauge needles and pen systems and offers flexible delivery that can be designed to for an immediate release dose followed by sustained delivery.

IPSCIO Record ID: 319352

License Grant
Licensor (of the United Kindgom) granted Licensee the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing Licensor’s spray formulation technology (Licensor Product), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses).
License Property
Topical Spray Technology product mean DSF100 or EpoladermTM and OSF200, a topical nonsteroidal anti-inflammatory drug. This Technology is a therapeutic treatment for topicals and transdermal deliveries due to its adhesion and accessibility properties, especially around joints and curved body surfaces.

OSF200 – for chronic osteoarthritis of the knee
DSF100 or EpoladermTM – for acute musculoskeletal pain

The product candidate is covered by US Patent No. 8,349,297. The patents contain broad composition claims to a platform of pharmaceutical formulations which form a film on spray administration where the active agent is present at least 80% saturation and there is no undissolved active agent in the formulation. The claims also include a method of treatment and an aerosol dispenser containing the formulation.

8,349,297 – Topical formulations

Field of Use
The field of use is for the treatment of pain to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses) and not limited to, treatment of estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain such as acute musculoskeletal pain and chronic osteoarthritis of the knee.

IPSCIO Record ID: 254416

License Grant
Licensor, a subsidiary, entered into an agreement with Licensee transfer the 499 Patent and related intellectual property.
License Property
The 499 Patent and related intellectual property is related to Products that involve anesthetizing a portion or all of a patient’s maxillary dental arch using a nasally delivered anesthetizing composition.  6,413,499 Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
Field of Use
The present invention relates to methods and systems for anesthetizing a patient's teeth and surrounding palatal tissues within the maxillary dental arch by means of a nasal deliverable anaesthetic. Such methods and systems eliminate altogether the need for painful needle injected local anesthetics when preparing a patient for dental work on the maxillary, or upper, dental arch. By this means, patients will have less fear and anxiety when visiting a dentist and will experience greatly decreased pain associated with the application of the local anesthetic preparatory to carrying out the actual dental procedure.

IPSCIO Record ID: 266812

License Grant
Licensor grants
—  an exclusive, even as to Licensor, royalty-bearing sublicense under the Licensor Rights with the right to sublicense, to import, use, sell and offer for sale Products in the Territory;
—  an exclusive, even as to Licensor, sublicense under the Licensor Rights, with the right to sublicense, to make and have made the Products in the Territory solely for import, use, sale and offer for sale within the territory or import and use in clinical trials in the Clinical Study Countries as permitted; and
—  an exclusive, even as to Licensor, sublicense under the Licensor Rights, with the right to sublicense, to make and have made the Products anywhere in the world solely for import, use, sale and offer for sale within the Territory, subject to the limitations set forth in an Agreement relating to parenteral paracetamol, or import or use in Licensees clinical trials in the Clinical Study Countries as permitted;
—  a non-exclusive license under the Licensors Patents, with the right to sublicense, to import, use, sell and offer for sale Products in the Territory;
—  a non-exclusive license under the Licensor Patents, with the right to sublicense, to make and have made the Products in the Terriitory solely for import, use, sale and offer for sale within the Territory;
—  a non-exclusive license under the Licensor Know-How, with the right to sublicense, to make and have made the Products anywhere in the world solely for use and sale within the Territory and import and use in clinical trials in the Clinical Study Countries as permitted; and,
—  a non-exclusive right to use, copy, translate, display and distribute, improve and make derivative works of the Licensor Technology Documentation for the purpose of making and having made the Products consistent with the license set forth above with respect to the Licensor Know-How.
License Property
Licensor has licensed a civil law partnership organized under the laws of France, rights under certain patents and patent applications relating to parenteral paracetamol.  Parenteral paracetamol is also referred to in the United States as acetaminophen.

Product means any parenterally administered dosage form containing paracetamol, or any Derivative thereof, alone or in combination with one or more other drugs, and for which the manufacture, use or sale in a country in the Territory would otherwise infringe any of the Licensed Patents or Licensors Patents but for the license rights granted by Licensor herein, and/or incorporates or uses to any material extent any Licensed Know-How and/or any parenterally administered dosage form containing paracetamol, or any Derivative thereof, alone or in combination with one or more other drugs that is manufactured by a process that incorporates or uses to any material extent any Licensor Know-How.

Field of Use
Licensee is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting.

Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers.

IPSCIO Record ID: 291115

License Grant
Licensor of Ireland grants to the Licensee, an entity formed by the Licensor and Licensee parent, for the term of the Agreement an exclusive license, with the right to grant sublicenses, for the territory to clinically test, register, have manufactured in accordance with the terms of this Agreement, to package, use, promote, distribute and sell the product  as a prescription medicine.

Licensor grants a non-exclusive license, with the right to grant sublicenses, in the territory for the term to use the Licensor trademark upon or in relation to the product.

License Property
Product shall mean the encapsulated SODAS® drug specific dosage forms in not more than four dosage strengths not exceeding 180mg.

The drug specificed for this agreement is Once-daily oral morphine capsules, containing SODAS® beads.

The trademark shall mean SODAS®.

The Product to be supplied to Licensee by Licensor shall be in the form of bulk two-piece hard gelatin capsules containing microparticulate SODAS® particles.

SODAS® (Spheroidal Oral Drug Absorption System) is Licensor’s Multiparticulate drug delivery system. Based on the production of controlled release beads, the SODAS® technology is characterized by its inherent flexibility, enabling the production of customized dosage forms that respond directly to individual drug candidate needs.

Field of Use
The license is  for a controlled release oral morphine pain relief product.

Licensor is knowledgeable in the development of drug specific dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments,

IPSCIO Record ID: 1208

License Grant
Licensor grants an exclusive license under the Technology to Develop, manufacture, have manufactured, import, use and Commercialize Products in the Field in the Territory, including the right to conduct clinical Development of the Products outside the Territory in support of Development and Commercialization of such Products in the Territory, including the right to grant sublicenses.

Licensor grants an exclusive license under the Technology, including foreign counterparts and equivalents of patent rights to the extent any exist, to manufacture and have manufactured Products outside the Territory in order to import, use and Commercialize Products in the Field in the Territory, including the right to grant sublicenses.

Licensor grants an exclusive license to use the Trademarks to Commercialize, including to advertise, promote and distribute, the Products in the Field in the Territory.

Licensor grants an exclusive license to exploit the Domain Names in connection with the Products.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has developed Aversion® Technology and related products intended to deter pharmaceutical product abuse.

Aversion® Composition means a composition having a gel forming polyethylene oxide, sodium lauryl sulfate, and crospovidone.

Product A means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 7.5mg with each tablet containing the Aversion® Composition with niacin at 30mg.

Product B means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 10.0mg with each tablet containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.

Product C means an immediate release Future Product in three tablet strengths hydrocodone bitartrate 5.0mg, 7.5mg, and 10.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.

Product D means an immediate release Future Product [in three tablet strengths hydromorphone HCl 2.0mg, 4.0mg, and 8.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg.

Trademarks means Aversion®, Acurox™, and Acuracet™.

The patents are for Methods and Compositions for Deterring Abuse of Opioid.

Acurox®, Acuracet® (oxycodone HCI/niacin/APAP) Tablets, Vycavert® (hydrocodone bitartrate/niacin/APAP) Tablets and a fourth undisclosed opioid analgesic product candidate utilizing our proprietary Aversion® Technology.

The Licensee has an option to License in the  territory all future opioid analgesic products developed utilizing Aversion® Technology. The Agreement provides that Licensor or Licensee may develop additional opioid analgesic product candidates utilizing our Aversion® Technology and, if Licensee exercises its option to License such additional product candidates, they will be subject to the milestone and royalty payments and other terms of the Agreement.

The drug is part of a class of opioid analgesic products for treatment for moderate to severe acute pain.

The Licensor is responsible, using commercially reasonable efforts, for all Acurox® Tablet development activities through FDA approval of a 505(b)(2) NDA, for which our expenses are reimbursed to us by the Licensee. After NDA approval the Licensee will be responsible for manufacturing and commercializing Acurox® Tablets in the U.S.

Field of Use
The Field means all present and future indications, as a human therapeutic, for use of the Products for the treatment of pain.

IPSCIO Record ID: 291110

License Grant
Canadian Licensor hereby grants to Licensee an exclusive license for the Field in the Territory under the Licensed Patents; and an exclusive license for the Field in the Territory under the Know-How; for the sole purpose of developing, making, having made, importing, using, offering for sale and selling Licensed Product in the Territory, including the right to grant sublicenses under these rights as set out in this Agreement.
License Property
Licensed Product means Ciprofloxacin encapsulated in the Licensor Liposome Technology and which is intended for pulmonary delivery.

Ciprofloxacin means the chemical compound known as ciprofloxacin, whose more specified chemical name is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and all pharmaceutically active salts thereof.

AERx Device means the durable hand-held device developed by Licensee for the delivery of Ciprofloxacin by inhalation and known as the AERx Device, as such device may be modified pursuant to the Agreement.

Loading Patents means the patents owned by University and exclusively licensed to Licensor and set out in Agreement.
5,800,833 – Method for loading lipid vesicles
5,785,987 – Method for loading lipid vesicles

Sphingosome Patents means the Patents owned by Licensor and set out in this Agreement.
5,543,152 – Sphingosomes for enhanced drug delivery

Licensed Patents means the Loading Patents and the Sphingosome Patents.

Patent means (a) all patent applications filed or having legal force in any country owned or controlled by Licensor as of the Effective Date; (b) all patents that have issued or in the future issue therefrom owned or controlled by Licensor as of the Effective Date, including without limitation utility, model and design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions (including supplemental protection certificates), additions, registrations or confirmations to or of any such patent applications and patents.

Licensor Liposome Technology means Licensor’s proprietary liposomal drug delivery system that encapsulates drugs in sphingomyelin/cholesterol liposomes using a proton gradient generated by either an ionophore or methylammonium sulfate.

Field of Use
This agreement pertains to patented liposomal formulation technology for the pulmonary delivery of ciprofloxacin

Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.